公开(公告)号：US20240216495A1

公开(公告)日：2024-07-04

申请号：US18446883

申请日：2023-08-09

Applicant: Pfizer Inc.

Inventor： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Robert G.K. Donald ,  Michael James Flint ,  Nicholas Randolph Everard Kitchin ,  Justin Keith Moran ,  Louise Pedneault ,  Michael W. Pride ,  Mark Edward Ruppen ,  Christopher Frederick Webber

IPC: A61K39/08 ,  A61K9/19 ,  A61K39/00

CPC classification number: A61K39/08 ,  A61K9/19 ,  A61K2039/545

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, wherein the second administration is about 30 days after the first administration, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.

公开(公告)号：US20240207257A1

公开(公告)日：2024-06-27

申请号：US18555058

申请日：2022-04-14

Applicant: IDEAYA BIOSCIENCES, INC. ,  PFIZER, INC.

Inventor： Matthew Anthony MAURER ,  Michael Gabriel O'QUIGLEY ,  Jaymes HOLLAND ,  Sarah Shwu-Kuan Jaw-Tsai ,  Julie Hambleton ,  MAI HOPE LE

IPC: A61K31/497 ,  A61K31/4184 ,  A61P35/00

CPC classification number: A61K31/497 ,  A61K31/4184 ,  A61P35/00

Abstract: Provided herein is a combination therapy and methods of using such combination therapy to treat diseases or disorders associated with PKC and MEK.

公开(公告)号：US20240197703A1

公开(公告)日：2024-06-20

申请号：US18144737

申请日：2023-05-08

Applicant: PFIZER INC.

Inventor： Joyann Barber ,  Sujin Cho-Schultz ,  Matthew L. Del Bel ,  Rebecca Anne Gallego ,  Mingying He ,  Mehran Jalaie ,  Robert Steven Kania ,  Michele Ann McTigue ,  Sajiv Krishnan Nair ,  Anne-Marie Dechert Schmitt ,  Jamison Bryce Tuttle ,  Dahui Zhou ,  Ru Zhou

IPC: A61K31/444 ,  A61K45/06 ,  C07D471/04 ,  C07D519/00

CPC classification number: A61K31/444 ,  A61K45/06 ,  C07D471/04 ,  C07D519/00

Abstract: This invention relates to compounds of general Formula I






and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US20240181071A1

公开(公告)日：2024-06-06

申请号：US18492055

申请日：2023-10-23

Applicant: Pfizer Inc.

Inventor： Andrea Therese HOOPER ,  Kimberly Ann MARQUETTE ,  Chakrapani SUBRAMANYAM ,  Hans-Peter GERBER ,  Chad Michael MAY

IPC: A61K47/68 ,  A61P35/00 ,  C07K16/18

CPC classification number: A61K47/6803 ,  A61K47/6843 ,  A61P35/00 ,  C07K16/18 ,  A61K38/08 ,  A61K47/6811

Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.

公开(公告)号：US20240181028A1

公开(公告)日：2024-06-06

申请号：US18513738

申请日：2023-11-20

Applicant: Pfizer Inc.

Inventor： Catherine Alex ,  Annaliesa Sybil Anderson ,  Bishwa Raj Bhetuwal ,  Zecheng Chen ,  Kaushik Dutta ,  Caitlyn Gallagher ,  Jianxin Gu ,  Isis Kanevsky ,  Jin-Hwan Kim ,  Justin Keith Moran ,  Suddham Singh ,  Naveen Surendran ,  Abhishek Ravindra Vartak ,  YuYing Yang

IPC: A61K39/09 ,  A61K47/64

CPC classification number: A61K39/092 ,  A61K47/646

Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in Prevnar, Synflorix and/or Prevnar 13. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

公开(公告)号：US20240180906A1

公开(公告)日：2024-06-06

申请号：US18283634

申请日：2022-03-21

Applicant: Pfizer Inc. ,  Astellas Pharma Inc.

Inventor： Akos Gabor Czibere ,  Dana Ann Kennedy

IPC: A61K31/5025 ,  A61K31/4166 ,  A61K45/06

CPC classification number: A61K31/5025 ,  A61K31/4166 ,  A61K45/06

Abstract: This invention relates to combination therapies comprising talazoparib, or a pharmaceutically acceptable salt thereof, and an anti-androgen, or a pharmaceutically acceptable salt thereof, and associated pharmaceutical compositions, methods of treatment, and pharmaceutical uses for the treatment of metastatic castration-sensitive prostate cancer in subjects identified as having at least one DNA damage repair gene mutation.

公开(公告)号：US20240173293A1

公开(公告)日：2024-05-30

申请号：US18549158

申请日：2022-03-02

Applicant: Sanofi ,  Pfizer Inc.

Inventor： Marina CELANOVIC ,  Gautier PAUX ,  Justin Thomas HOFFMAN ,  Sandrine ANNEHEIM ,  Sylvaine CARTOT-COTTON ,  Patrick COHEN ,  Alice GOSSELIN

IPC: A61K31/40 ,  A61K9/00 ,  A61K31/519 ,  A61P35/04

CPC classification number: A61K31/40 ,  A61K9/0053 ,  A61K31/519 ,  A61P35/04

Abstract: The present disclosure provides methods of treating breast cancer with a combination of amcenestrant and palbociclib.

公开(公告)号：US11981696B2

公开(公告)日：2024-05-14

申请号：US16980616

申请日：2019-03-14

Applicant: Pfizer Inc.

Inventor： Tamim Fehme Braish ,  Matthew Frank Brown ,  Ye Che ,  Richard Andrew Ewin ,  Timothy Allan Johnson ,  Michael Joseph Melnick ,  Justin Ian Montgomery ,  Mark Stephen Plummer ,  Loren Michael Price ,  Usa Reilly ,  Daniel Uccello

IPC: C07F9/58 ,  A61P31/04 ,  C07F5/02

CPC classification number: C07F9/58 ,  A61P31/04 ,  C07F5/022

Abstract: The present invention is directed to a new fluoro-pyridinone hydroxamic acid phosphates and boronates of Formulae I, II and III




wherein Q is selected from the group consisting of —P(O)(OH)2, —P(O)(OH)(O−M+), —P(O)(O−M+)2 and —P(O)(O−)2M2+; M+ at each occurrence is a pharmaceutically acceptable monovalent cation; and M2+ is a pharmaceutically acceptable divalent cation and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

公开(公告)号：US20240150394A1

公开(公告)日：2024-05-09

申请号：US18322395

申请日：2023-05-23

Applicant: PFIZER INC.

Inventor： Durgesh V. Nadkarni ,  Jeffry R. Borgmeyer ,  He Meng ,  Qingping Jiang

IPC: C07K1/18 ,  A61K47/68

CPC classification number: C07K1/18 ,  A61K47/6811 ,  A61K47/6849

Abstract: Methods of removing high molecular weight species, in particular aggregates, from antibody drug conjugate preparations, by contacting preparations of the antibody drug conjugate reaction mixture with a hydroxyapatite resin and selectively eluting the ADC from the resin using a gradient comprising sodium phosphate.

公开(公告)号：US20240150299A1

公开(公告)日：2024-05-09

申请号：US18414019

申请日：2024-01-16

Applicant: PFIZER INC.

Inventor： Elaine GREER ,  Stephen ANDERSON ,  Mark MALONEY ,  Shu YU ,  Ekaterina ALBERT ,  Emily RIGSBEE

IPC: C07D233/88

CPC classification number: C07D233/88 ,  A61K31/40 ,  C07B2200/13

Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.